Mirae Asset Global Investments Co., Ltd. Pro Qr Therapeutics N.V. Transaction History

Mirae Asset Global Investments Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$0.56 - $1.0 $88,222 - $157,540	-157,540 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$0.9 - $8.39 $26,210 - $244,341	-29,123 Reduced 15.6%	157,540 $143,000
Q4 2021 Feb 08, 2022	BUY	$6.58 - $8.44 $232,017 - $297,602	35,261 Added 23.29%	186,663 $1.5 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $146,126 - $239,861	28,319 Added 23.01%	151,402 $1.27 Million
Q2 2021 Aug 11, 2021	BUY	$5.75 - $7.59 $707,727 - $934,199	123,083 New	123,083 $830,000
Q4 2020 Feb 10, 2021	SELL	$3.58 - $4.85 $144,424 - $195,658	-40,342 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$4.79 - $6.3 $60,976 - $80,199	12,730 Added 46.1%	40,342 $193,000
Q2 2020 Aug 11, 2020	BUY	$4.5 - $6.53 $53,163 - $77,145	11,814 Added 74.78%	27,612 $168,000
Q1 2020 May 12, 2020	BUY	$5.25 - $9.9 $8,982 - $16,938	1,711 Added 12.15%	15,798 $87,000
Q4 2019 Feb 12, 2020	BUY	$5.84 - $10.51 $82,268 - $148,054	14,087 New	14,087 $140,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.